This report provides a comprehensive analysis of the global ophthalmology drugs market, projecting steady growth driven by an aging population and the rising prevalence of age-related eye diseases. It examines key segments, including monoclonal antibodies and fusion proteins, while highlighting technological advancements in gene therapies and sustained-release implants. The study covers various molecules, indications, and administration routes across major global regions, with particular focus on the United States' rapid expansion. Furthermore, it evaluates competitive dynamics, regulatory landscapes, and emerging opportunities within biosimilars and developing economies.

Market Overview

The global ophthalmology drugs market is projected to grow from USD 19.52 billion in 2025 to USD 26.28 billion by 2030, registering a CAGR of 6.1% during the forecast period.

Market Dynamics

Growth Drivers

• Prevalence of Disease: Increasing prevalence of age-related eye diseases.
• Therapeutic Availability: Availability of several key therapies addressing these conditions.
• Drug Pipeline: A robust pipeline of new drugs across various treatment modalities.
• Innovation: Growing innovation efforts and a strong drug pipeline.
• Investment & Collaboration: Increasing investments and strategic collaborations.
• Reimbursement: Improved reimbursement policies.

Market Restraints

• Off-label Use: Off-label drug use for various indications.

Market Opportunities

• New Modalities: Shifting focus on new drug modalities.
• Geographic Expansion: Expansion into emerging markets, including Asia Pacific, Latin America, the Middle East, and Africa.
• Unmet Needs: High levels of unmet medical needs.

Market Challenges

• Treatment Adherence: Frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment.

Segment Analysis

By Modality

• Monoclonal Antibodies & Fusion Proteins: This segment is expected to grow at the highest CAGR during the study period. Growth is driven by unmet needs in treating retinal diseases, advancements in drug delivery, recent product approvals, and the introduction of biosimilars and upcoming products like KSI-301. Key factors include the adoption of these treatments in emerging markets due to better access, affordable pricing (particularly via biosimilars), and less frequent dosing. Innovations such as sustained-release implants and gene therapies also contribute to this sector's growth.
• Small Molecules
• Other Modalities

By Molecule

• Aflibercept
• Faricimab
• Ranibizumab
• Other molecules

By Indication

• Age-related macular degeneration (AMD)
• Diabetic macular edema (DME)
• Diabetic retinopathy
• Other indications

By Route of Administration

• Intravitreal
• Topical
• Other routes of administration

By End User

• Hospitals
• Long-term care facilities
• Specialty centers

Regional Analysis

Global Perspective

• Opportunities for expansion exist in emerging economies such as Asia Pacific, Latin America, the Middle East, and Africa.

United States

The US is expected to experience the highest CAGR in the global ophthalmology drugs market between 2025 and 2035. This rapid growth is driven by:

• Demographics: An aging population.
• Disease Prevalence: High prevalence of age-related macular degeneration (AMD) and diabetic macular edema (DME).
• Medical Needs & Approvals: Significant unmet medical needs and recent drug approvals such as Syfovre and Izervay.
• Innovation Pipeline: A promising pipeline for gene and cell therapies.
• Ecosystem: A strong research and development ecosystem, efficient FDA approval processes, and robust investment.
• Economic Factors: A favorable reimbursement environment, Medicare coverage, and a willingness to adopt expensive therapies.

Competitive Landscape

Key Market Dynamics for Players

Market dynamics are significantly influenced by payor acceptance and technological innovations. Key players are vital for market growth.

Key Companies Profiled

• AbbVie (US)
• Apellis Pharmaceuticals (US)
• Astellas Pharma Inc. (US)
• Bayer AG (Germany)
• Biogen (US)
• Bausch + Lomb (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Formycon AG (Germany)
• Novartis AG (Switzerland)
• Regeneron, Pharmaceuticals Inc. (US)
• Among others

Research Methodology

Primary Interview Categorization

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Report Scope & Benefits

Research Coverage

• Major Factors: Detailed analysis of drivers, restraints, challenges, and opportunities.
• Company Analysis: Business overview, products, solutions, key strategies, collaborations, partnerships, agreements, new approvals/launches, acquisitions, and recent developments.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, pipeline analysis, investment/funding activities, brand/product comparative analysis, and vendor valuation/financial metrics.
• Market Development: Analysis of lucrative markets and regional variations.
• Market Diversification: Information on new products, untapped geographies, recent developments, and investments.
• Product Development/Innovation: Insights into upcoming products, R&D activities, and new product launches.

Key Benefits of the Report

• For Market Leaders & New Entrants: Provides close approximations of revenue numbers for the market and its subsegments.
• For Stakeholders: Facilitates a better understanding of the competitive landscape to improve business positioning and go-to-market strategies. Provides insight into the 'market pulse' regarding drivers, restraints, opportunities, and challenges.

• 1 INTRODUCTION 31

  • 1.1 STUDY OBJECTIVES 31

  • 1.2 MARKET DEFINITION 31

  • 1.3 STUDY SCOPE 32

    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 32

    • 1.3.2 INCLUSIONS & EXCLUSIONS 33

    • 1.3.3 YEARS CONSIDERED 34

    • 1.3.4 CURRENCY CONSIDERED 34

  • 1.4 STAKEHOLDERS 34

• 2 RESEARCH METHODOLOGY 35

  • 2.1 RESEARCH DATA 35

    • 2.1.1 SECONDARY DATA 36

      • 2.1.1.1 Objectives of secondary research 36
      • 2.1.1.2 Key data from secondary sources 37

    • 2.1.2 PRIMARY DATA 37

      • 2.1.2.1 Breakdown of primaries (supply- and demand-side participants) 38
      • 2.1.2.2 Key objectives of primary research 38

  • 2.2 MARKET ESTIMATION METHODOLOGY 39

    • 2.2.1 GLOBAL MARKET ESTIMATION 39

      • 2.2.1.1 Product revenue analysis (bottom-up approach) 39
      • 2.2.1.2 Revenue share analysis of Regeneron Pharmaceuticals, Inc 40
      • 2.2.1.3 MnM repository analysis 41
      • 2.2.1.4 Primary interviews 41

    • 2.2.2 INSIGHTS OF PRIMARY EXPERTS 41

    • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (BOTTOM-UP APPROACH) 42

  • 2.3 MARKET GROWTH RATE PROJECTIONS 43

  • 2.4 DATA TRIANGULATION 45

  • 2.5 STUDY ASSUMPTIONS 45

  • 2.6 RESEARCH LIMITATIONS 46

  • 2.7 RISK ANALYSIS 46

• 3 EXECUTIVE SUMMARY 47

• 4 PREMIUM INSIGHTS 51

  • 4.1 OPHTHALMOLOGY DRUGS MARKET OVERVIEW 51

  • 4.2 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE 52

  • 4.3 OPHTHALMOLOGY DRUGS MARKET SHARE, BY END USER, 2024 52

  • 4.4 OPHTHALMOLOGY DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53

• 5 MARKET OVERVIEW 54

  • 5.1 INTRODUCTION 54

  • 5.2 MARKET DYNAMICS 54

    • 5.2.1 DRIVERS 55

      • 5.2.1.1 Aging population and growing prevalence of vision disorders 55
      • 5.2.1.2 Strong drug pipeline and growing innovation efforts 56
      • 5.2.1.3 Increasing investments and strategic collaborations 57
      • 5.2.1.4 Improved reimbursement policies 57

    • 5.2.2 RESTRAINTS 58

      • 5.2.2.1 Off-label drug use for various indications 58

    • 5.2.3 OPPORTUNITIES 59

      • 5.2.3.1 Shifting focus on new drug modalities 59
      • 5.2.3.2 Expansion into emerging markets 60
      • 5.2.3.3 High unmet needs 61

    • 5.2.4 CHALLENGES 61

      • 5.2.4.1 Frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment 61

  • 5.3 TECHNOLOGY ANALYSIS 62

    • 5.3.1 KEY TECHNOLOGIES 63

      • 5.3.1.1 Hybridoma technology 63
      • 5.3.1.2 Recombinant DNA technology 63
      • 5.3.1.3 Antibody engineering 64
      • 5.3.1.4 Gene therapy 64
      • 5.3.1.5 Nanoformulations 65

    • 5.3.2 ADJACENT TECHNOLOGIES 65

      • 5.3.2.1 Optogenetic technology 65
      • 5.3.2.2 Drug-release technologies 66
      • 5.3.2.3 Ocular implant technologies 66

    • 5.3.3 COMPLEMENTARY TECHNOLOGIES 66

      • 5.3.3.1 3D printing and bioprinting 66
      • 5.3.3.2 Ocular imaging technologies 67

  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67

  • 5.5 PRICING ANALYSIS 67

    • 5.5.1 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024 68

    • 5.5.2 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024 68

    • 5.5.3 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024 69

  • 5.6 VALUE CHAIN ANALYSIS 69

  • 5.7 ECOSYSTEM ANALYSIS 71

    • 5.7.1 OPHTHALMOLOGY DRUGS MARKET: ROLE OF RAW MATERIAL SUPPLIERS 72

    • 5.7.2 OPHTHALMOLOGY DRUGS MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES 73

    • 5.7.3 OPHTHALMOLOGY DRUGS MARKET: ROLE OF END USERS 74

    • 5.7.4 OPHTHALMOLOGY DRUGS MARKET: ROLE OF REGULATORY AUTHORITIES 74

  • 5.8 PATENT ANALYSIS 75

  • 5.9 REGULATORY ANALYSIS 76

    • 5.9.1 REGULATORY LANDSCAPE 76

      • 5.9.1.1 US 77
      • 5.9.1.2 Europe 78
      • 5.9.1.3 Emerging markets 78

    • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79

  • 5.10 PORTER’S FIVE FORCES ANALYSIS 82

    • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY 84

    • 5.10.2 BARGAINING POWER OF SUPPLIERS 84

    • 5.10.3 BARGAINING POWER OF BUYERS 84

    • 5.10.4 THREAT OF SUBSTITUTES 84

    • 5.10.5 THREAT OF NEW ENTRANTS 85

  • 5.11 KEY CONFERENCES & EVENTS, 2025-2026 85

  • 5.12 REIMBURSEMENT SCENARIO 86

  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA 86

    • 5.13.1 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS 87

  • 5.14 INVESTMENT & FUNDING SCENARIO 88

  • 5.15 PIPELINE ANALYSIS 89

  • 5.16 IMPACT OF ARTIFICIAL INTELLIGENCE ON OPHTHALMOLOGY DRUGS MARKET 92

    • 5.16.1 CHALLENGES IN DRUG DISCOVERY 93

    • 5.16.2 IMPACT OF AI ON DISCOVERY OF OPHTHALMOLOGY DRUGS 93

  • 5.17 IMPACT OF 2025 US TARIFFS ON OPHTHALMOLOGY DRUGS MARKET 94

    • 5.17.1 KEY TARIFF RATES 94

    • 5.17.2 PRICE IMPACT ANALYSIS 95

    • 5.17.3 KEY IMPACT ON VARIOUS REGIONS 96

      • 5.17.3.1 US 96
      • 5.17.3.2 Europe 96
      • 5.17.3.3 APAC 96

    • 5.17.4 MANUFACTURING INDUSTRY IMPACT 97

      • 5.17.4.1 Ophthalmology drug manufacturers 97

• 6 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE 98

  • 6.1 INTRODUCTION 99

  • 6.2 AFLIBERCEPT 99

    • 6.2.1 HIGH EFFICIENCY OF AFLIBERCEPT IN TREATING RETINAL DISEASES TO DRIVE MARKET GROWTH 99

  • 6.3 FARICIMAB 102

    • 6.3.1 GROWING ADOPTION AND POSITIVE OUTCOMES OF STUDIES TO SUPPORT MARKET GROWTH 102

  • 6.4 RANIBIZUMAB 105

    • 6.4.1 CLINICAL EFFICACY OF RANIBIZUMAB TO DRIVE ADOPTION 105

  • 6.5 OTHER MOLECULES 108

• 7 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY 112

  • 7.1 INTRODUCTION 113

  • 7.2 MONOCLONAL ANTIBODIES & FUSION PROTEINS 113

    • 7.2.1 GROWING FOCUS ON DEVELOPING NEW MABS TO DRIVE MARKET 113

  • 7.3 SMALL MOLECULES 116

    • 7.3.1 INCREASING INVESTMENTS AND RESEARCH TO DRIVE MARKET 116

  • 7.4 OTHER MODALITIES 119

• 8 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION 123

  • 8.1 INTRODUCTION 124

  • 8.2 AGE-RELATED MACULAR DEGENERATION 124

    • 8.2.1 WET AGE-RELATED MACULAR DEGENERATION 127

      • 8.2.1.1 Increasing demand for effective therapies to drive market 127

    • 8.2.2 DRY AGE-RELATED MACULAR DEGENERATION 130

      • 8.2.2.1 Large market opportunity for innovation to drive growth 130

  • 8.3 DIABETIC RETINOPATHY (DR) 131

    • 8.3.1 FEWER APPROVED DRUGS TO PRESENT MARKET OPPORTUNITIES 131

  • 8.4 DIABETIC MACULAR EDEMA (DME) 133

    • 8.4.1 GROWING ADOPTION OF APPROVED ANTI-VEGF DRUGS FOR DME

  • 8.5 OTHER INDICATIONS 136

• 9 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION 139

  • 9.1 INTRODUCTION 140

  • 9.2 INTRAVITREAL 140

    • 9.2.1 HIGH EFFICACY OF INTRAVITREAL INJECTIONS IN TREATMENT OF MAJOR RETINAL DISEASES TO DRIVE MARKET 140

  • 9.3 TOPICAL 143

    • 9.3.1 EASE OF USE TO DRIVE DEMAND FOR TOPICAL DRUGS 143

  • 9.4 OTHER ROUTES OF ADMINISTRATION 145

• 10 OPHTHALMOLOGY DRUGS MARKET, BY END USER 148

  • 10.1 INTRODUCTION 149

  • 10.2 HOSPITALS 149

    • 10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO ENCOURAGE GROWTH 149

  • 10.3 LONG-TERM CARE FACILITIES 152

    • 10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET 152

  • 10.4 SPECIALTY CENTERS 154

    • 10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS

• 11 OPHTHALMOLOGY DRUGS MARKET, BY REGION 158

  • 11.1 INTRODUCTION 159

  • 11.2 NORTH AMERICA 159

    • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 160

    • 11.2.2 US 164

      • 11.2.2.1 Rising investments in healthcare research and development

    • 11.2.3 CANADA 167

      • 11.2.3.1 Rising government initiatives to support ophthalmology drugs research and increasing drug approvals to support growth 167

  • 11.3 EUROPE 170

    • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 170

    • 11.3.2 GERMANY 175

      • 11.3.2.1 Rising focus on clinical research to drive market 175

    • 11.3.3 UK 178

      • 11.3.3.1 Ongoing advancements in technology to drive market growth 178

    • 11.3.4 FRANCE 181

      • 11.3.4.1 Growing investments and government support to drive market growth 181

    • 11.3.5 ITALY 183

      • 11.3.5.1 Growing investments and research to support market 183

    • 11.3.6 SPAIN 186

      • 11.3.6.1 Growing geriatric population to drive market growth 186

    • 11.3.7 REST OF EUROPE 189

  • 11.4 ASIA PACIFIC 191

    • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 191

    • 11.4.2 CHINA 195

      • 11.4.2.1 Large diabetic population to boost market 195

    • 11.4.3 JAPAN 198

      • 11.4.3.1 Growing aging population to intensify demand for effective treatments 198

    • 11.4.4 INDIA 201

      • 11.4.4.1 Increasing diabetic cases, government support, and growing availability of biosimilars to support market 201

    • 11.4.5 AUSTRALIA 203

      • 11.4.5.1 Strong biopharmaceutical sector to drive market growth 203

    • 11.4.6 SOUTH KOREA 206

      • 11.4.6.1 Strong R&D pipeline and increasing focus on research to support growth 206

    • 11.4.7 REST OF ASIA PACIFIC 209

  • 11.5 LATIN AMERICA 211

    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 211

    • 11.5.2 BRAZIL 215

      • 11.5.2.1 Significant rates of visual impairment in region to drive demand

    • 11.5.3 MEXICO 218

      • 11.5.3.1 Growing research initiatives and innovations to support

    • 11.5.4 REST OF LATIN AMERICA 221

  • 11.6 MIDDLE EAST 224

    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 224

    • 11.6.2 GCC COUNTRIES 227

      • 11.6.2.1 Growing research initiatives and improving healthcare infrastructure to support growth 227

    • 11.6.3 REST OF MIDDLE EAST 230

  • 11.7 AFRICA 233

    • 11.7.1 GROWING FOCUS ON HEALTHCARE TO DRIVE MARKET GROWTH 233

    • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 233

• 12 COMPETITIVE LANDSCAPE 237

  • 12.1 INTRODUCTION 237

  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 237

    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET 237

  • 12.3 REVENUE ANALYSIS, 2022-2024 238

  • 12.4 MARKET SHARE ANALYSIS, 2024 239

  • 12.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2024 242

    • 12.5.1 STARS 242

    • 12.5.2 EMERGING LEADERS 242

    • 12.5.3 PERVASIVE PLAYERS 242

    • 12.5.4 PARTICIPANTS 242

    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 244

      • 12.5.5.1 Company footprint 244
      • 12.5.5.2 Region footprint 245
      • 12.5.5.3 Molecule footprint 246
      • 12.5.5.4 Modality footprint 247
      • 12.5.5.5 Indication footprint 248

  • 12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024 249

    • 12.6.1 PROGRESSIVE COMPANIES 249

    • 12.6.2 RESPONSIVE COMPANIES 249

    • 12.6.3 DYNAMIC COMPANIES 249

    • 12.6.4 STARTING BLOCKS 249

    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 251

      • 12.6.5.1 Detailed list of key startups/SMEs 251
      • 12.6.5.2 Competitive benchmarking of startups/SMEs 252

  • 12.7 COMPANY VALUATION & FINANCIAL METRICS 253

    • 12.7.1 VALUATION OF KEY PLAYERS 253

    • 12.7.2 FINANCIAL METRICS OF KEY PLAYERS 253

  • 12.8 BRAND/PRODUCT COMPARISON 254

  • 12.9 COMPETITIVE SCENARIO 255

    • 12.9.1 PRODUCT LAUNCHES & APPROVALS 255

    • 12.9.2 DEALS 256

• 13 COMPANY PROFILES 257

  • 13.1 KEY PLAYERS 257

    • 13.1.1 REGENERON PHARMACEUTICALS INC 257

      • 13.1.1.1 Business overview 257
      • 13.1.1.2 Products offered 258
      • 13.1.1.3 Recent developments 259
        • 13.1.1.3.1 Product approvals 259
      • 13.1.1.4 MnM view 259
        • 13.1.1.4.1 Right to win 259
        • 13.1.1.4.2 Strategic choices 259
        • 13.1.1.4.3 Weaknesses & competitive threats 260

    • 13.1.2 F. HOFFMANN-LA ROCHE LTD 261

      • 13.1.2.1 Business overview 261
      • 13.1.2.2 Products offered 262
      • 13.1.2.3 Recent developments 263
        • 13.1.2.3.1 Product launches & approvals 263
      • 13.1.2.4 MnM view 264
        • 13.1.2.4.1 Right to win 264
        • 13.1.2.4.2 Strategic choices 264
        • 13.1.2.4.3 Weaknesses & competitive threats 265

    • 13.1.3 BAYER AG 266

      • 13.1.3.1 Business overview 266
      • 13.1.3.2 Products offered 267
      • 13.1.3.3 Recent developments 268
        • 13.1.3.3.1 Product approvals 268
      • 13.1.3.4 MnM view 268
        • 13.1.3.4.1 Right to win 268
        • 13.1.3.4.2 Strategic choices 269
        • 13.1.3.4.3 Weaknesses & competitive threats 269

    • 13.1.4 NOVARTIS AG 270

      • 13.1.4.1 Business overview 270
      • 13.1.4.2 Products offered 271
      • 13.1.4.3 Recent developments 272
        • 13.1.4.3.1 Product approvals 272
        • 13.1.4.3.2 Deals 272
      • 13.1.4.4 MnM view 273
        • 13.1.4.4.1 Right to win 273
        • 13.1.4.4.2 Strategic choices 273
        • 13.1.4.4.3 Weaknesses & competitive threats 273

    • 13.1.5 ABBVIE 274

      • 13.1.5.1 Business overview 274
      • 13.1.5.2 Products offered 275

    • 13.1.6 APELLIS PHARMACEUTICALS 276

      • 13.1.6.1 Business overview 276
      • 13.1.6.2 Products offered 277
      • 13.1.6.3 Recent developments 278
        • 13.1.6.3.1 Product approvals 278
        • 13.1.6.3.2 Deals 278

    • 13.1.7 BIOGEN 279

      • 13.1.7.1 Business overview 279
      • 13.1.7.2 Products offered 280
      • 13.1.7.3 Recent developments 281
        • 13.1.7.3.1 Product launches & approvals 281

    • 13.1.8 BAUSCH + LOMB 283

      • 13.1.8.1 Business overview 283
      • 13.1.8.2 Products offered 285
      • 13.1.8.3 Recent developments 287
        • 13.1.8.3.1 Product launches & approvals 287

    • 13.1.9 ASTELLAS PHARMA INC 288

      • 13.1.9.1 Business overview 288
      • 13.1.9.2 Products offered 289
      • 13.1.9.3 Recent developments 290
        • 13.1.9.3.1 Product approvals 290
        • 13.1.9.3.2 Deals 290

    • 13.1.10 FORMYCON AG 291

      • 13.1.10.1 Business overview 291
      • 13.1.10.2 Products offered 292
      • 13.1.10.3 Recent developments 293
        • 13.1.10.3.1 Product launches & approvals 293
        • 13.1.10.3.2 Deals 294

    • 13.1.11 BIOCON 295

      • 13.1.11.1 Business overview 295
      • 13.1.11.2 Products offered 296
      • 13.1.11.3 Recent developments 296
        • 13.1.11.3.1 Product approvals 296
        • 13.1.11.3.2 Deals 296

    • 13.1.12 SANDOZ GROUP AG 297

      • 13.1.12.1 Business overview 297
      • 13.1.12.2 Products offered 298
      • 13.1.12.3 Recent developments 299
        • 13.1.12.3.1 Product approvals 299
        • 13.1.12.3.2 Deals 299

    • 13.1.13 SANTEN PHARMACEUTICAL CO., LTD 300

      • 13.1.13.1 Business overview 300
      • 13.1.13.2 Products offered 301
      • 13.1.13.3 Recent developments 302
        • 13.1.13.3.1 Product launches 302

    • 13.1.14 INNOVENT 303

      • 13.1.14.1 Business overview 303
      • 13.1.14.2 Products offered 304
      • 13.1.14.3 Recent developments 304
        • 13.1.14.3.1 Product approvals 304

    • 13.1.15 OUTLOOK THERAPEUTICS, INC 305

      • 13.1.15.1 Business overview 305
      • 13.1.15.2 Products offered 305
      • 13.1.15.3 Recent developments 306
        • 13.1.15.3.1 Product approvals 306
        • 13.1.15.3.2 Deals 306

    • 13.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD 307

      • 13.1.16.1 Business overview 307
      • 13.1.16.2 Products offered 308
      • 13.1.16.3 Recent developments 309
        • 13.1.16.3.1 Product approvals 309
        • 13.1.16.3.2 Deals 310

  • 13.2 OTHER PLAYERS (PIPELINE COMPANIES) 311

    • 13.2.1 OCULAR THERAPEUTIX, INC 311

    • 13.2.2 OPTHEA LIMITED 312

    • 13.2.3 KODIAK SCIENCES INC 313

    • 13.2.4 EYEPOINT PHARMACEUTICALS, INC 314

    • 13.2.5 ALVOTECH 315

    • 13.2.6 CLEARSIDE BIOMEDICAL 316

    • 13.2.7 SHANGHAI HENLIUS BIOTECH, INC 317

    • 13.2.8 ADVERUM BIOTECHNOLOGIES, INC 318

    • 13.2.9 REMEGEN 319

    • 13.2.10 SPARINGVISION 320

• 14 APPENDIX 321

  • 14.1 DISCUSSION GUIDE 321

  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 325

  • 14.3 CUSTOMIZATION OPTIONS 327

  • 14.4 RELATED REPORTS 327

  • 14.5 AUTHOR DETAILS 328